![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
Presentation of HER2/neu Vaccine Development Program at Third Annual Cancer Vaccines and Active Immunity Summit, Boston, June 27-29, 2012
June 26, 2012 09:20 ET
|
TapImmune Inc.
SEATTLE, June 26, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc (OTCBB:TPIV) has announced it will present a poster at the Third Annual Cancer Vaccines and Active Immunotherapy Summit in Boston describing...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Inc. to Present at NYC Medtech Forum on June 14, 2012
June 13, 2012 12:43 ET
|
TapImmune Inc.
SEATTLE, June 13, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (TPIV.OB), a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Announces the Appointment of James W. Fuller to the Board of Directors
May 18, 2012 09:15 ET
|
TapImmune Inc.
SEATTLE, May 18, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has pleasure in announcing the appointment of James W. Fuller to the Board of Directors.
James (Jim) Fuller has over 30 years of...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
Phase I Clinical Trials on HER2/neu Antigens to Start at Mayo Clinic
May 04, 2012 09:10 ET
|
TapImmune Inc.
SEATTLE, May 4, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has announced that following recent IRB approval a Phase I Clinical Trial on a novel set of HER2/neu Class II antigens will start...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Announces the Appointment of Mark Reddish to the Board of Directors
April 30, 2012 09:30 ET
|
TapImmune Inc.
SEATTLE, April 30, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has pleasure in announcing the appointment of Mark Reddish to the Board of Directors. Mark is currently Vice President of...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Announces the Appointment of Mr. George Cardona as Strategic Advisor to the Board
April 19, 2012 09:30 ET
|
TapImmune Inc.
SEATTLE, April 19, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has pleasure in announcing the appointment of George Cardona as a Strategic Advisor to the Board on corporate strategy and...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Licenses HER2/neu Antigen Technology from Mayo Clinic for Incorporation Into a Vaccine to Treat HER2/neu Breast Cancer
April 16, 2012 06:00 ET
|
TapImmune Inc.
SEATTLE, Wash., April 16, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has announced that it has signed an Exclusive Agreement with the Mayo Foundation for Education & Research, Rochester,...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Appoints Dr. Robert Florkiewicz as Senior Director of Molecular Biology & Virology
April 11, 2012 09:20 ET
|
TapImmune Inc.
SEATTLE, April 11, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has announced that Robert Florkiewicz, Ph.D., has been appointed Senior Director of Molecular Biology & Virology.
"Bob has...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Inc. to Present at BioPartnering North America
February 27, 2012 09:30 ET
|
TapImmune Inc.
SEATTLE, Feb. 27, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a vaccine technologies company specializing in the development of innovative immunotherapeutics and vaccines in the areas of...
![TapImmune Logo](/news-release/logo/216780/0/216780.jpg?lastModified=12%2F09%2F2016%2022%3A52%3A09&size=2)
TapImmune Chairman and CEO Provides Corporate Update to Current and Future Shareholders
January 30, 2012 09:30 ET
|
TapImmune Inc.
SEATTLE, Jan. 30, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), Chairman and CEO is pleased to provide this corporate update to our shareholders and other interested parties.
I am pleased to...